The US market is the focus for the company at the moment,...

The US market is the focus for the company at the moment, that's where the growth is happening and is where 99% of marketing resources are being allocated. It also makes up the vast majority of their revenue. Last half that was up 65%, first couple months of this year were also up a similarly high rate. That was on a reasonably large base and before the significant expansion in their sales team (from only 6 reps previously) and marketing effort though, and based on an explosion in social media activity around iTrack Advance and significant increase in their presence at the major conferences, it seems fairly likely we will see this growth rate accelerate (particularly in the second half of calendar year 2025, but also the current half as well). Given they're not yet focused on the global market outside the US, global growth has been lagging (they have existing revenue from the previous device) which makes the over all figure look a little less exciting. However I suspect when they focus more resources outside the US, and they get more approvals in these markets, the growth rate will be as strong as it has been in the USA (particularly in China).

They have a large number of patents protecting the key features of their device, thanks to originally pioneering the canaloplasty space with their original iTrack device. Sight Sciences tried to create a similar device, but it's not even close. It can only do half of an eye at a time (not the full eye all at once), has no navigational system and no pressurised visco delivery (which means they get about 10% of the strength of iTrack Advance - requiring the use of an additional tearing procedure).